Defining the Role of TCF21 in Adventitial Fibroblasts in Atherosclerosis
About This Grant
PROJECT SUMMARY Coronary artery disease (CAD) remains a rising cause of morbidity and mortality in the United States. Human genetics suggest that a significant portion of the inheritable risk of CAD is related to fibroblast-specific regions of the genome. Using single cell transcriptomics, our group has identified a transcriptionally distinct adventitial fibroblast (AdvFib) population, which undergoes early phenotypic modulation during atherosclerosis development. Specific ablation of AdvFib significantly reduces plaque burden, suggesting their ability to influence atherosclerosis. To identify regulators of AdvFib, we characterized regions of altered chromatin accessibility upon AdvFib activation, revealing the transcription factor Tcf21. Tcf21 is predominantly expressed in AdvFib, and its expression declines upon AdvFib phenotypic activation. Tcf21 knockout in murine AdvFib increases vascular calcifications and upregulation of pro-atherogenic inflammatory cytokines. Given the restricted expression of Tcf21 to AdvFib and phenotypic activation of AdvFib upon Tcf21 knockdown, the central hypothesis underlying this proposal is that overexpression of Tcf21 locks AdvFib in a quiescent state, which then prevents the downstream activation of non-cell-autonomous signals that trigger plaque formation. Using an AdvFib-specific Tcf21 overexpression mouse model, I will characterize histological changes in plaque and alterations in non-AdvFib plaque cells, such as smooth muscle cells and inflammatory cells. I will then use single-cell RNA sequencing to characterize transcriptional changes of AdvFib upon Tcf21 overexpression and downstream transcriptional changes in non-AdvFib plaque cells. Given the putative effect of Tcf21 on the activation/recruitment of inflammatory cells, my goal is to characterize the precise epigenetic regions of Tcf21 binding to understand how Tcf21 regulates inflammatory cytokine production. Overall, this study will elucidate the role of AdvFib in atherosclerosis and characterize how Tcf21 regulates AdvFib.
Grant Summary
Defining the Role of TCF21 in Adventitial Fibroblasts in Atherosclerosis is a NHLBI - National Heart Lung and Blood Institute grant providing up to $83K for university, nonprofit, healthcare org. Applications are due 2028-12-31 (open). Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 9,000+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
How to Apply
Up to $83K
2028-12-31
- 1Confirm your organization is eligible for Defining the Role of TCF21 in Adventitial Fibroblasts in Atherosclerosis from NHLBI - National Heart Lung and Blood Institute, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NHLBI - National Heart Lung and Blood Institute before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NHLBI - National Heart Lung and Blood Institute's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Defining the Role of TCF21 in Adventitial Fibroblasts in Atherosclerosis: Frequently Asked Questions
Who is eligible for the Defining the Role of TCF21 in Adventitial Fibroblasts in Atherosclerosis?
Defining the Role of TCF21 in Adventitial Fibroblasts in Atherosclerosis is offered by NHLBI - National Heart Lung and Blood Institute and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Defining the Role of TCF21 in Adventitial Fibroblasts in Atherosclerosis provide?
Defining the Role of TCF21 in Adventitial Fibroblasts in Atherosclerosis provides up to $83K per award from NHLBI - National Heart Lung and Blood Institute. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Defining the Role of TCF21 in Adventitial Fibroblasts in Atherosclerosis deadline?
Applications for Defining the Role of TCF21 in Adventitial Fibroblasts in Atherosclerosis are due 2028-12-31 (open). Because deadlines can change, verify the date with the funder, NHLBI - National Heart Lung and Blood Institute, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Defining the Role of TCF21 in Adventitial Fibroblasts in Atherosclerosis?
To apply for Defining the Role of TCF21 in Adventitial Fibroblasts in Atherosclerosis, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NHLBI - National Heart Lung and Blood Institute.